Biotech News

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026

Dermata Therapeutics (DRMA)Dermata Therapeutics2026-06-25 13:46 ESTEarnings

DRMA (DRMA) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is drma.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

DRMADermata Therapeutics2026-06-25 13:46 EST

Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

DRMADermata Therapeutics2026-06-25 13:46 EST

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

DRMADermata Therapeutics2026-06-25 13:46 EST

A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity

DRMADermata Therapeutics2026-06-25 13:46 EST

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

DRMADermata Therapeutics2026-06-25 13:46 EST

Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

DRMADermata Therapeutics2026-06-25 13:46 EST

Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office

DRMADermata Therapeutics2026-06-25 13:46 EST

Dermata Opens a New Chapter with the Release of Tome Skincare

DRMADermata Therapeutics2026-06-25 13:46 EST

Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing

DRMADermata Therapeutics2026-06-25 13:46 EST

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025

DRMADermata Therapeutics2026-06-25 13:46 EST

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System

View all latest news

Dermata Therapeutics

Dermata Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

DRMADermata Therapeutics2026-06-26 14:48 EST

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026

DRMADermata Therapeutics2026-06-26 14:48 EST

Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

DRMADermata Therapeutics2026-06-26 14:48 EST

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

DRMADermata Therapeutics2026-06-26 14:48 EST

A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity

DRMADermata Therapeutics2026-06-26 14:48 EST

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States